Summary of IIPR-PA Q1 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenues: $69 million, a 3.5% increase from Q4 2025.

Adjusted Funds from Operations (AFFO): $53.4 million, or $1.88 per share, consistent with the previous quarter.

Liquidity: Approximately $177 million, consisting of $89 million in cash and $87.5 million available under revolving credit facilities.

Debt Metrics: Debt service coverage ratio exceeding 11x and net debt to adjusted EBITDA at 1.1x.

2Strategic Updates and Business Highlights

The rescheduling of cannabis from Schedule I to Schedule III is seen as a significant regulatory milestone, potentially enhancing the operational environment for medical cannabis operators.

IIPR raised $128 million in gross proceeds year-to-date and is pursuing an additional $130 million in financing to address upcoming bond maturities and support growth.

The company signed new leases totaling approximately 331,000 square feet across four properties, indicating strong demand for its facilities.

IIPR has made progress in resolving tenant issues, including reaching agreements with former tenants PharmaCann and Gold Flora.

3Forward Guidance and Outlook

The management team remains optimistic about the cannabis market's future, particularly with the potential for expanded medical programs and the upcoming administrative hearings on cannabis rescheduling.

The company is focusing on refinancing its unsecured debt and completing its commitment to IQHQ before pursuing further growth opportunities.

IIPR expects to continue benefiting from the strengthening cannabis industry and is positioned to capitalize on new leasing opportunities.

4Bad News, Challenges, or Points of Concern

The company faces ongoing macroeconomic challenges, including inflation and elevated interest rates, which could impact operations.

There are still unresolved tenant issues, particularly with Battle Green, which defaulted on lease obligations.

The uncertainty surrounding the timeline and outcomes of the administrative hearings could pose risks to the anticipated benefits of rescheduling.

5Notable Q&A Insights

Management indicated that while the rescheduling is a positive development, it does not address interstate commerce or banking issues, which remain significant hurdles for the cannabis industry.

There is cautious optimism regarding future credit issues for tenants, as 280E relief may improve their financial situations, but management acknowledged that risks inherent to business operations will persist.

The company is exploring acquisition opportunities in the cannabis sector, particularly in states with expanding medical programs, while prioritizing the completion of refinancing efforts. Overall, IIPR demonstrated a solid financial performance in Q1 2026, with strategic initiatives aimed at capitalizing on a changing regulatory landscape and addressing tenant challenges. However, macroeconomic pressures and unresolved tenant issues remain points of concern.